Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022

Submitted by amarin on Tue, 02/15/2022 - 13:01
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's fourth quarter and full year 2021 financial results on Tuesday,

Amarin Provides Preliminary 2021 Revenue and Outlook for 2022

Submitted by amarin on Mon, 01/10/2022 - 12:02
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited full-year 2021 revenue results. Amarin plans to discuss these results and expectations with investors in connection with

Amarin to Present at the 40th Annual J.P. Morgan Healthcare Conference

Submitted by amarin on Tue, 01/04/2022 - 12:01
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to present virtually at the 40 th Annual J.P.

Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021

Submitted by amarin on Tue, 11/16/2021 - 12:00
VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32% in patients with prior PAD DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today reported an overview of new data relating to

Amarin to Present at Two Upcoming Investor Conferences

Submitted by amarin on Thu, 11/11/2021 - 12:00
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, and Michael Kalb, chief financial officer of Amarin, are scheduled to participate in the following

Latest Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) to be Presented at American Heart Association Scientific Sessions 2021

Submitted by amarin on Mon, 11/08/2021 - 12:00
Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Three Presentations Also Featuring Virtual Exhibit Booth, Digital Product Theater and On-Line Continuing Medical Education Programming DUBLIN, Ireland and BRIDGEWATER, N.J., Nov.

Amarin Reports Third Quarter 2021 Financial Results and Provides Business Update

Submitted by amarin on Wed, 11/03/2021 - 10:00
Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022 Introduced New Go-to-Market Strategy in U.S. to Enhance Awareness and Drive Demand for VASCEPA® Plans for Regulatory Filings and Approvals of VASCEPA in Several Additional Countries in 2022 Company to Host

Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

Submitted by amarin on Wed, 10/20/2021 - 11:05
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarin’s senior management team to discuss the Company's third quarter 2021 financial results on Wednesday,

Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.

Submitted by amarin on Wed, 09/22/2021 - 13:15
Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to accelerate